Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib combined with S-1 in metastatic colorectal cancer
NCT06746545Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Fujian Medical University Cancer Hospital. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06746545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746545.